转移性嫌色细胞肾细胞癌接受靶向治疗:肾交叉通道组研究
该研究为肾交叉通道组内的回顾性数据分析,纳入26个中心的91例转移性嫌色细胞肾细胞癌(mChRCC)患者,评估靶向治疗时代的总体缓解、总生存(OS)和治疗失败时间(TTF)。61例接受靶向治疗者中50例(82%)用抗血管生成(AA)药物、11例用mTOR抑制剂;一线AA与mTOR抑制剂之间TTF(p=0.26)和OS(p=0.55)均无显著差异。
要点
- 91例mChRCC患者来自26个中心,自首次转移起中位随访6.1年(范围0-13.9)。
- 自转移诊断起中位OS为37.9个月(95%CI 21.4-46.8)。
- 一线AA与mTOR抑制剂的TTF(p=0.26)与OS(p=0.55)均无显著差异。
核心结论
- 作者报告了迄今最大的接受靶向治疗的mChRCC回顾性队列,抗血管生成药物与mTOR抑制剂在TTF和OS上均无显著差异。
研究设计与样本
- 肾交叉通道组内的回顾性数据分析,纳入26个中心的91例转移性嫌色细胞肾细胞癌患者;终点为总体缓解、总生存(OS)和治疗失败时间(TTF),后两者采用Kaplan-Meier法估计。
主要发现
- 自首次转移日期起中位随访6.1年(范围0-13.9)。
- 自转移性疾病诊断起中位OS为37.9个月(95%CI 21.4-46.8)。
- 61例接受靶向治疗的患者中,50例(82%)接受抗血管生成(AA)治疗,11例接受mTOR抑制剂治疗。
- 一线AA的中位TTF为8.7个月(95%CI 5.2-10.9)、中位OS为22.9个月(95%CI 17.8-49.2),mTOR抑制剂分别为1.9个月(95%CI 1.0-6.0)和3.2个月(95%CI 2.3-不可评估)。
- 采用分层log-rank检验比较AA与mTOR抑制剂靶向治疗并控制国际转移性RCC数据库联盟风险组效应,TTF(p=0.26)与OS(p=0.55)均无显著差异。
临床怎么用
- 作者结论为抗血管生成药物与mTOR抑制剂在mChRCC的TTF和OS上无显著差异,原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC. METHODS: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan-Meier method. RESULTS: 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0-13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4-46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2-10.9) and 22.9 months (95% CI: 17.8-49.2) versus 1.9 months (95% CI: 1.0-6.0) and 3.2 months (95% CI: 2.3-not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55). CONCLUSION: We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.
引用
- Colomba E, Le Teuff G, Eisen T, et al. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. Eur J Cancer. 2017. PMID: 28549248. doi:10.1016/j.ejca.2017.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。